Akums Drugs and Pharmaceuticals: The financial results for the period ended September 30, 2026
Akums Drugs and Pharmaceuticals (AKUMS) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹11,517 crore.
What happened
Akums Drugs and Pharmaceuticals (AKUMS) filed a disclosure with the exchanges on 2 November 2026 at 05:14 PM titled "The financial results for the period ended September 30, 2026".
From the filing: "Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026."
Company snapshot
Akums Drugs and Pharmaceuticals is a small-cap company in the Healthcare sector, with a market value of about ₹11,517 crore.
The stock last traded at ₹731.7, against a 52-week range of ₹409.3–₹838.8 (12.8% below the high).
Before this filing the shares had moved −10.7% over the month and +11.1% over three months. Average daily turnover over the last 20 sessions was about ₹15.05 crore.
Promoters held 75.26% at the end of Q1 FY27. Foreign institutions owned 1.91% and domestic institutions 13.44%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,024 | 63.5 | 4.15 |
| Q2 FY26 | 1,018 | 40.8 | 2.66 |
| Q3 FY26 | 1,160 | 66.3 | 4.33 |
| Q4 FY26 | 1,158 | 84.6 | 5.53 |
| Q1 FY27 | 1,167 | 100 | 6.53 |
What history shows
BCEIE's records show 2 previous results filings from the company since May 2026.
After those filings, the stock gained 9.1% on average the next trading day and was up 6.7% on average after five days (2 filings with price data).
Across 300 similar disclosures by other Healthcare companies, shares moved +1.1% on average the next day and +1.7% over five days; 56% of them rose the next day.
Market-wide, 10,143 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 8 Aug 2026 | 'Un-audited Financial Results for the Quarter ended 30th June, 2026'. | +9.1% | +6.7% |
| 8 Aug 2026 | , the financial results for the period ended Jun 30, 2026. | +9.1% | +6.7% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 2 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.